BioSight
Companies
Kiniksa Pharmaceuticals International, plc logo

KNSA

NASDAQLONDON
Kiniksa Pharmaceuticals International, plc

Kiniksa Pharmaceuticals develops medicines for inflammatory and autoimmune diseases using subcutaneous injection and oral modalities. The pipeline includes KPL-387, a candidate in Phase 2 testing for recurrent pericarditis expected to generate data in the second half of 2026, and KPL-1161, which is planned to enter Phase 1 clinical testing by the end of 2026. Kiniksa also markets ARCALYST, an approved product for certain inflammatory conditions.

Price history not yet available for KNSA.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar